One infusion of FDA-approved Monoferric can provide a full course of IV iron therapy in as little as 20 minutes[1,*]

1 1000 MG VIAL = **1** FULL COURSE OF TREATMENT = **1** INFUSION APPOINTMENT

INDICATION[1]

Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients:

- who have intolerance to oral iron or have had unsatisfactory response to oral iron
- who have non-hemodialysis dependent chronic kidney disease (NDD-CKD)

ONLY MONOFERRIC IS FDA-APPROVED AS A SINGLE, RAPID IRON INFUSION, REGARDLESS OF PATIENT WEIGHT[1,*]

RECOMMENDED DOSAGE[1]:

- **For patients weighing 50 kg or more:** Administer 1000 mg by IV infusion over at least 20 minutes as a single dose
- **For patients weighing less than 50 kg:** Administer as 20 mg/kg actual body weight by IV infusion over at least 20 minutes as a single dose
- Repeat Monoferric treatment if iron deficiency anemia reoccurs
- Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions
- Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion

*Monoferric is administered as a single, 1-g IV infusion for patients weighing ≥50 kg, or 20 mg/kg for patients <50 kg, over ≥20 minutes. Repeat dose if iron deficiency anemia reoccurs. Patients should be monitored for an additional 30 minutes post-infusion.

SELECT IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Monoferric is contraindicated in patients with a history of serious hypersensitivity to Monoferric or any of its components. Reactions have included shock, clinically significant hypotension, loss of consciousness, and/or collapse.

Please see additional Important Safety Information on next page and accompanying Full Prescribing Information.

See Full Prescribing Information for clinical study data.
Please contact PTI directly or the local representative for details.

READILY AVAILABLE THROUGH WHOLESALERS AND DISTRIBUTORS

STORAGE AND HANDLING[1]

Monoferric injection is a sterile, dark brown, nontransparent aqueous solution supplied in cartons as single-dose vials.

Vial size	Number of vials per carton	NDC (for billing purposes)
1000 mg	1	73594-9310-1

Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). See the USP controlled room temperature. Do not freeze.

Healthcare Common Procedure Coding System (HCPCS) Code[2]

HCPCS CODE	DESCRIPTOR	SITE OF CARE
J1437	Injection, ferric derisomaltose, 10 mg	All sites of care

3 EASY WAYS TO FIND COVERAGE AND ACCESS INFORMATION WITH MONOFERRIC PATIENT SOLUTIONS®[a]

1. Visit us at **monoferric.com/access-support/monoferric-patient-solutions-program/**

2. Call **1-800-992-9022** if you have questions or need support over the phone (Monday to Friday, from 8 AM to 8 PM ET except holidays)

3. Email us at **MonferricPatientSolutions@Pharmacosmos.us**

[a]Monoferric Patient Solutions provides educational support only and does not submit claims or perform administrative services on behalf of providers. Program participation does not guarantee insurance coverage, product access, or reimbursement. Eligibility and restrictions apply. Final coverage decisions are made by payors.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Monoferric. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Monoferric administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Monoferric when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. Monoferric is contraindicated in patients with prior serious hypersensitivity reactions to Monoferric or any of its components. In clinical trials in patients with IDA and CKD, serious or severe hypersensitivity were reported in 0.3% (6/2008) of the Monoferric treated subjects. These included 3 events of hypersensitivity in 3 patients; 2 events of infusion-related reactions in 2 patients and 1 event of asthma in one patient.

Iron Overload

Excessive therapy with parenteral iron can lead to excess iron storage and possibly iatrogenic hemosiderosis or hemochromatosis. Monitor the hematologic response (hemoglobin and hematocrit) and iron parameters (serum ferritin and transferrin saturation) during parenteral iron therapy. Do not administer Monoferric to patients with iron overload.

ADVERSE REACTIONS

Adverse reactions were reported in 8.6% (172/2008) of patients treated with Monoferric. Adverse reactions related to treatment and reported by ≥1% of the treated patients were nausea (1.2%) and rash (1%). Adjudicated serious or severe hypersensitivity reactions were reported in 6/2008 (0.3%) patients in the Monoferric group. Hypophosphatemia (serum phosphate <2.0 mg/dL) was reported in 3.5% of Monoferric-treated patients in Trials 1 & 2.

To report adverse events, please contact Pharmacosmos at 1-888-828-0655. You may also contact the FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see additional Important Safety Information on previous page and accompanying Full Prescribing Information.

References: 1. Monoferric (ferric derisomaltose) Prescribing Information; Pharmacosmos Therapeutics Inc., Morristown, NJ: 2022. **2.** HCPCS Quarterly Update. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update Accessed April 2, 2026.

PHARMACOSMOS THERAPEUTICS